

**ASSESSMENT OF THE ANTIPROTOZOAL
ACTIVITY OF SOME TUBULIN INHIBITORS
FOLLOWING CYCLODEXTRIN
COMPLEXATION.**

By

Kathleen I. Menon BSc. Hons. (Biological Science)

This thesis was submitted as a requirement for the degree of Doctor of
Philosophy at Murdoch University 2002.

DECLARATION

I declare that the thesis ‘Assessment of the antiprotozoal activity of some tubulin inhibitors following complexation with cyclodextrin’ is a true account of my own research. To the best of my knowledge, the work submitted is original and contains no material that has previously been submitted for a degree at any tertiary education institution.

Kathleen I. Menon

ACKNOWLEDGEMENTS

Firstly, I would sincerely like to thank my supervisors Professors James Reynoldson and Andrew Thompson for their guidance and patience over the years, and persistence of these attributes while reading and correcting drafts of my thesis. I also extend my thanks to the Division of Veterinary and Biomedical Sciences, Murdoch University, for the provision of research funding and financial assistance with conference travel expenses which made my studies possible.

Many thanks to Associate Professors Charles McDonald and John Parkin from Curtin University for their help with the HPLC and phase solubility experiments, and especially Mike Boddy for teaching me HPLC and for always being there when I needed help.

Thanks also go to Professor Douglas Clarke and Kenneth Seymour from the Chemistry department at Murdoch University for their help with the DSC-TGA analysis.

I am also grateful to the staff and students in the Vet school at Murdoch University (both past and present) for their help on various aspects of my project. In particular, special thanks to Anthony Armson, Megan Johnson, Keith Sargent, Geoff Dow, Nawal Hijjawi and Andrew Low from the Parasitology group, and to Ken Chong from the Biochemistry group, for both their friendship and help throughout this PhD.

Finally, and most of all, I would like to thank my husband Prakash for his support, belief and love throughout the duration of this project.

ABSTRACT

The purpose of the present study was to evaluate the potential usefulness of tubulin inhibitors when complexed with hydroxypropyl- β -cyclodextrin (HP β CD) against a range of protozoan parasites. This approach involved investigations into the complexation of these drugs with HP β CD, and subsequent investigations of these drugs and their complexes in regard to cytotoxicity, pharmacokinetics, *in vitro* efficacy against *Giardia*, *Cryptosporidium* and rodent malaria (*Plasmodium chabaudi*), and their *in vivo* efficacy against *Giardia* and malaria.

Albendazole (ABZ) is a benzimidazole carbamate with a broad anti-parasite spectrum, while the dinitroanilines trifluralin (TF) and oryzalin (OZ) have recently been found to exhibit activity against certain parasites. All three compounds are microtubule antagonists in either nematodes or weeds and have poor aqueous solubility, with the solubility of ABZ and OZ dependent on pH. Cyclodextrins (CD) have a hydrophobic cavity that allows them to form inclusion complexes with hydrophobic drugs, resulting in increased drug aqueous solubility, and often, improved drug dissolution and bioavailability. Thus the complexation of these drugs with HP β CD was investigated. All three compounds exhibited type A_L phase solubility diagrams with HP β CD complexation, with additional increases in ABZ and OZ solubility achieved through the manipulation of temperature and pH. OZ displayed a stronger interaction with HP β CD when ionised over its neutral form. However, insufficient concentrations of the TF/HP β CD complex were achieved for drug efficacy studies.

The cytotoxicity of the drugs and their complexes was assessed using the assay kit Cytotox 96 with human carcinoma cells. This is a colourimetric assay that measures lactate dehydrogenase release as a consequence of compromised cellular and membrane integrity. Both ABZ and OZ are cytotoxic to rapidly proliferating and differentiating cells but are not cytotoxic to cells in the stationary phase. Complexation did not affect drug cytotoxicity. In pharmacokinetic studies, complexation improved ABZ (and metabolites) bioavailability, but had no significant affect on OZ bioavailability. *In vitro* drug assessment studies found ABZ to be highly effective against *Giardia*, and effective

against *Cryptosporidium* and malaria. OZ on the other hand exhibited no activity against *Giardia*, but was effective against *Cryptosporidium* and malaria. Complexation did not improve the antiprotozoal efficacy of either ABZ or OZ. In particular, excess HP β CD decreased the anti-*Giardia* effects of ABZ, possibly due to competitive complex formation. In addition, complexation did not improve the antiprotozoal effects of ABZ *in vivo*. However, the cytotoxic effect of the ABZ/HP β CD complex was more evident in the treatment of malaria *in vivo*, resulting in increased anaemia and suppression in weight gain, due to the improved bioavailability of ABZ and metabolites.

HP β CD alone was found to be cytotoxic at greater than 2.5%, and inhibited *Giardia* both *in vitro* and *in vivo* at greater than 1% and 2% respectively. This was attributed to membrane disruption caused by the dissolution and removal of membrane components. In comparison, malaria grew better in the presence of HP β CD *in vitro*, with no detrimental effect observed at up to 8% HP β CD. This was attributed to either the increased solubilization of a necessary media component, or the complexation and removal of an inhibitory compound from the cultivation medium.

Therefore HP β CD complexation did not improve the antiprotozoal activity of the tubulin antagonists ABZ and OZ. However, the results of the pharmacokinetic studies suggest that anthelmintic activity of ABZ, particularly against systemic infections, may be improved with oral administration of the ABZ/HP β CD complex. In addition, the antiparasitic activity of HP β CD alone may be promising, especially against intestinal infections. Finally, the improved *in vitro* cultivation of *P. chabaudi* in the presence of HP β CD presents a promising approach to its potential long term cultivation.

TABLE OF CONTENTS

Declaration	ii
Acknowledgements	iii
Abstract	iv
Table of Contents	vi
Abbreviations	xiii
List of Figures	xiv
List of Tables	xviii
List of Tables	xviii
<i>Chapter 1. Literature Review</i>	<i>1</i>
1.1. The need for improved drug delivery systems	2
1.1.1. Formulation design	3
1.1.1.1. Complexation	5
1.2. Cyclodextrins	5
1.2.1. Structure and physiochemical properties	5
1.2.2. Synthesis and degradation	7
1.2.3. Biological effects	9
1.2.3.1. Oral administration	9
1.2.3.2. Parenteral administration	10
1.3. Cyclodextrin complexation	11
1.3.1. Solubilization	11
1.3.2. Stability	13
1.3.3. Complex formation	15
1.4. Cyclodextrin derivatives	16
1.4.1. Characteristics	16
1.4.2. Types of derivatives	18
1.4.2.1. Alkylated cyclodextrin derivatives	19
1.4.2.2. Hydroxyalkylated cyclodextrin derivatives	20
1.4.2.3. Branched cyclodextrin derivatives	21
1.4.2.4. Polymerised cyclodextrin derivatives	22
1.4.2.5. Ionic cyclodextrin derivatives	22
1.5. Hydroxypropyl-β-cyclodextrin	23
1.5.1. Characteristics	23
1.5.2. Manufacture	26
1.5.3. Biological effects	27
1.5.3.1. Oral administration	27
1.5.3.2. Parenteral administration	28
1.6. Formulation of inclusion complexes	30
1.6.1. Determination of stability constants	30
1.6.1.1. Phase solubility analysis	31
1.6.2. Analysis of cyclodextrin complexes	33
1.6.3. Solid inclusion compounds	34
1.6.4. Improving complexation efficiency	35
1.7. Conclusion	37
1.7.1. Safety issues	37
1.7.2. Applications	38
1.8. Rationale and Aim	39

Chapter 2. Complexation of the Tubulin Inhibitors Albendazole, Oryzalin and Trifluralin with HPβCD	41
2.1. Introduction	42
2.1.1. Tubulin	42
2.1.2. Benzimidazoles	44
2.1.2.1. Mode of action	46
2.1.2.2. Resistance	47
2.1.2.3. Albendazole	48
2.1.2.3.1. Characteristics	48
2.1.2.3.2. Metabolism	49
2.1.2.3.3. Toxicity	49
2.1.3. Dinitroanilines	51
2.1.3.1. Mode of action	52
2.1.3.2. Resistance	52
2.1.3.3. Trifluralin	53
2.1.3.3.1. Characteristics	53
2.1.3.3.2. Degradation	54
2.1.3.3.3. Toxicity	56
2.1.3.4. Oryzalin	57
2.1.3.4.1. Characteristics	57
2.1.3.4.2. Degradation and toxicity	58
2.1.4. Improving drug efficacy through formulation design	58
2.1.5. Aim	59
2.2. Methods	60
2.2.1. Phase-solubility analysis	60
2.2.2. Albendazole/HP β CD complex formulation	60
2.2.2.1. HPLC conditions	60
2.2.2.2. Detection and quantitation limits	61
2.2.2.3. ABZ/HP β CD complex formation analysis	62
2.2.2.4. Effect of pH on ABZ solubility	62
2.2.2.5. Effect of pH on ABZ/HP β CD complex formation	62
2.2.3. Trifluralin/HP β CD complex formulation	63
2.2.3.1. HPLC conditions	63
2.2.3.2. Detection and quantitation limits	63
2.2.3.3. Measurement of TF	65
2.2.3.4. TF/HP β CD complex formation	65
2.2.3.5. Effect of pH on TF solubility	65
2.2.4. Oryzalin /HP β CD complex formulation	66
2.2.4.1. HPLC conditions	66
2.2.4.2. Detection and quantitation limits	66
2.2.4.3. OZ/HP β CD complex formation	66
2.2.4.4. Effect of pH on OZ solubility	66
2.2.4.5. Effect of pH on OZ/HP β CD complex formation	68
2.2.5. Verification of complex formation	68
2.2.6. Glassware	69
2.2.7. Statistical analysis	69
2.3. Results	70
2.3.1. Albendazole/HP β CD complex formulation	70
2.3.1.1. Effect of HP β CD on ABZ solubility	70

2.3.1.2. The effect of pH on ABZ/HP β CD complex formation	71
2.3.2. Trifluralin/HP β CD complex formulation	76
2.3.2.1. Measurement of TF	76
2.3.2.2. Effect of HP β CD on TF solubility	76
2.3.3. Oryzalin/HP β CD complex formulation	78
2.3.3.1. Effect of HP β CD on OZ solubility	78
2.3.3.2. The effect of pH on OZ/HP β CD complex formation	80
2.3.4. DSC-TGA analysis	83
2.3.4.1. ABZ complex formation	83
2.3.4.2. OZ complex formation	83
2.4. Discussion	86
2.4.1. Albendazole	86
2.4.1.1. Phase solubility analysis	86
2.4.1.2. Temperature	87
2.4.1.3. pH	88
2.4.1.4. DSC-TGA	88
2.4.2. Trifluralin	89
2.4.2.1. Phase solubility analysis	89
2.4.2.2. Temperature	90
2.4.3. Oryzalin	91
2.4.3.1. Phase solubility analysis	91
2.4.3.2. Temperature	91
2.4.3.3. pH	92
2.4.3.4. DSC-TGA	93
2.4.4. Conclusion	93
Chapter 3. Pharmacokinetics of the Drug/HPβCD Complexes	95
3.1. Introduction	96
3.1.1. Oral formulations	96
3.1.2. Parenteral formulations	100
3.1.3. Aim	101
3.2. Methods	102
3.2.1. Origin and housing of experimental animals	102
3.2.2. Pharmacokinetic experiments	102
3.2.2.1. <i>In vivo</i> albendazole pharmacokinetic study design	102
3.2.2.1.1. Pharmacokinetics of the ABZ/HP β CD complex	102
3.2.2.1.2. Pharmacokinetics of a commercial ABZ formulation	103
3.2.2.2. <i>In vivo</i> oryzalin pharmacokinetic study design	104
3.2.2.2.1. OZ/HP β CD pharmacokinetic experiment	104
3.2.2.2.2. OZ pharmacokinetic experiment	104
3.2.3. HPLC analysis	104
3.2.3.1. HPLC analysis of albendazole	104
3.2.3.1.1. UV spectrum	104
3.2.3.1.2. HPLC conditions	104
3.2.3.1.3. HPLC standards	106
3.2.3.1.4. Sample preparation	107
3.2.3.1.5. Extraction validation	107
3.2.3.2. HPLC analysis of oryzalin	109
3.2.3.2.1. HPLC conditions	109
3.2.3.2.2. HPLC standards	109

3.2.3.2.3. Sample preparation	109
3.2.3.2.4. Extraction validation	110
3.2.4. Statistical analysis	110
3.3. Results	112
3.3.1. Albendazole	112
3.3.1.1. Albendazole chromatography and standard curves	112
3.3.1.2. Albendazole extraction validation	112
3.3.1.3. Albendazole pharmacokinetics	115
3.3.1.3.1. ABZ pharmacokinetics at 6 mg kg ⁻¹	115
3.3.1.3.2. ABZ pharmacokinetics at 30 mg kg ⁻¹	117
3.3.2. Oryzalin	117
3.3.2.1. Oryzalin chromatography and standard curves	117
3.3.2.2. Oryzalin extraction validation	120
3.3.2.3. Oryzalin pharmacokinetics	121
3.4. Discussion	123
3.4.1. Albendazole	123
3.4.1.1. Pharmacokinetics of ABZ (Valbazen®) at 6 mg kg ⁻¹	123
3.4.1.2. Pharmacokinetics of ABZ/HPβCD complex at 6 mg kg ⁻¹	123
3.4.1.3. Pharmacokinetics of ABZ (Suspension) at 30 mg kg ⁻¹	124
3.4.1.4. Pharmacokinetics of ABZ/HPβCD complex (pH 2.1) at 30 mg kg ⁻¹	124
3.4.2. Oryzalin	126
3.4.2.1. Pharmacokinetics of OZ	126
3.4.2.2. Pharmacokinetics of OZ/HPβCD complex	126
3.4.3. Complexation behaviour of inclusion compounds in the gastrointestinal tract	127
3.4.4. Conclusion	128
Chapter 4. Cytotoxicity and In Vivo Consumption of HPβCD Complexes	130
4.1. Introduction	131
4.1.1. Cellular interactions of CDs	131
4.1.2. Effect of CD on drug membrane diffusion	133
4.1.3. Aim	134
4.2. Methods	135
4.2.1. Cytotoxicity of drug/HPβCD complexes and HPβCD	135
4.2.1.1. Preparation of HCT-8 cells	135
4.2.1.2. Administration of drugs	135
4.2.1.3. CytoTox 96 assay procedure	136
4.2.1.4. Calculations	136
4.2.1.5. Statistical analysis	137
4.2.2. HPβCD consumption <i>in vivo</i>	137
4.2.2.1. Origin and housing of experimental animals	137
4.2.2.2. HPβCD consumption	137
4.3. Results	138
4.3.1. Cytotoxicity of drug/HPβCD complexes and HPβCD alone	138
4.3.1.1. Cytotoxicity of drug formulations	138
4.3.1.2. Cytotoxicity of HPβCD	138
4.3.2. HPβCD consumption	139
4.4. Discussion	141
4.4.1. Drug cytotoxicity	141
4.4.1.1. Albendazole	141

4.4.1.2. Oryzalin	142
4.4.1.3. Effect of complexation on drug cytotoxicity	143
4.4.2. HP β CD cytotoxicity	143
4.4.3. HP β CD consumption	144
Chapter 5. Antigiardial Effects of the Drug/HPβCD Complexes	145
5.1. Introduction	146
5.1.1. <i>Giardia</i>	146
5.1.1.1. Lifecycle	146
5.1.1.2. Morphology	146
5.1.1.3. <i>Giardia</i> species	149
5.1.2. Giardiasis	149
5.1.2.1. Prevalence and transmission	149
5.1.2.2. Disease and diagnosis	150
5.1.2.3. Treatment and prevention	151
5.1.3. Benzimidazole action against <i>Giardia</i>	152
5.1.4. Aim	153
5.2. Methods	154
5.2.1. Maintenance of <i>G. duodenalis</i> <i>in vivo</i> and <i>in vitro</i>	154
5.2.1.1. Cultivation of <i>G. duodenalis</i> <i>in vitro</i>	154
5.2.1.1.1. Culture medium for <i>G. duodenalis</i> trophozoites	154
5.2.1.1.2. Removal of <i>G. duodenalis</i> trophozoites from cryopreservation	154
5.2.1.1.3. Cultivation of <i>G. duodenalis</i> trophozoites	155
5.2.1.1.4. Cryopreservation of <i>G. duodenalis</i> trophozoites	155
5.2.1.2. Amplification of <i>G. duodenalis</i> <i>in vivo</i>	156
5.2.1.2.1. Origin and housing of experimental animals	156
5.2.1.2.2. Infection and amplification of <i>G. duodenalis</i> <i>in vivo</i>	156
5.2.1.2.3. Cryopreservation of <i>G. duodenalis</i> trophozoites amplified <i>in vivo</i>	156
5.2.2. Efficacy experiments against <i>G. duodenalis</i> <i>in vitro</i>	157
5.2.2.1. Drug efficacy experiments	157
5.2.2.2. Administration of drugs	157
5.2.2.3. Determination of <i>in vitro</i> drug efficacy - counting of trophozoites	158
5.2.3. Efficacy experiments against <i>G. duodenalis</i> <i>in vivo</i>	159
5.2.3.1. Origin and housing of experimental animals	159
5.2.3.2. Efficacy of ABZ and ABZ/HP β CD against <i>G. duodenalis</i> <i>in vivo</i>	159
5.2.3.3. ABZ drug regime	160
5.2.3.4. ABZ/HP β CD drug regime	160
5.2.3.5. HP β CD regime	160
5.2.4. Statistical analysis	161
5.3. Results	162
5.3.1. Efficacy experiments against <i>G. duodenalis</i> (P1c10) <i>in vitro</i>	162
5.3.1.1. Effect of HP β CD on <i>G. duodenalis</i> <i>in vitro</i>	162
5.3.1.2. ABZ efficacy against <i>G. duodenalis</i> <i>in vitro</i>	163
5.3.1.3. Dinitroaniline efficacy against <i>G. duodenalis</i> <i>in vitro</i>	165
5.3.2. ABZ efficacy experiments against <i>G. duodenalis</i> (Rat 4) <i>in vivo</i>	165
5.3.2.1. Effect of HP β CD on <i>G. duodenalis</i> <i>in vivo</i>	165
5.3.2.2. ABZ efficacy against <i>G. duodenalis</i> <i>in vivo</i>	165
5.4. Discussion	168
5.4.1. Effect of HP β CD on <i>G. duodenalis</i>	168

5.4.1.1. <i>In vitro</i>	168
5.4.1.2. <i>In vivo</i>	168
5.4.2. Drug efficacy	169
5.4.2.1. <i>In vitro</i>	169
5.4.2.2. <i>In vivo</i>	171
5.4.3. Conclusion	173
Chapter 6. <i>In Vitro</i> Anticryptosporidial Effects of the Drug/HPβCD Complexes	174
6.1. Introduction	175
6.1.1. <i>Cryptosporidium</i>	175
6.1.1.1. Lifecycle	175
6.1.1.2. <i>Cryptosporidium</i> species	175
6.1.2. Human cryptosporidiosis	177
6.1.2.1. Prevalence and transmission	177
6.1.2.2. Disease and diagnosis	178
6.1.2.3. Treatment and prevention	178
6.1.3. Development of <i>in vitro</i> drug assays for <i>C. parvum</i>	179
6.1.4. Aim	181
6.2. Methods	182
6.2.1. Maintenance of <i>C. parvum</i> <i>in vivo</i> and <i>in vitro</i>	182
6.2.1.1. Cultivation of <i>C. parvum</i> <i>in vivo</i>	182
6.2.1.1.1. Origin and housing of experimental animals	182
6.2.1.1.2. Infection and collection of <i>C. parvum</i> oocysts <i>in vivo</i>	182
6.2.1.1.3. Ficoll gradients	183
6.2.1.2. Cultivation of <i>C. parvum</i> <i>in vitro</i>	183
6.2.1.2.1. Culture medium for the cultivation of HCT-8 cells	183
6.2.1.2.2. Removal of HCT-8 cells from cryopreservation	184
6.2.1.2.3. Cultivation of HCT-8 cells	184
6.2.1.2.4. Cryopreservation of HCT-8 cells	184
6.2.1.2.5. Excystation of <i>C. parvum</i> oocysts for <i>in vitro</i> cultivation	185
6.2.1.2.6. Cultivation of <i>C. parvum</i> <i>in vitro</i>	185
6.2.2. Efficacy experiments against <i>C. parvum</i> <i>in vitro</i>	186
6.2.2.1. Drug efficacy experiments	186
6.2.2.2. Administration of drugs	186
6.2.3. Quantification of <i>in vitro</i> parasite growth	187
6.2.3.1. DNA extraction	187
6.2.3.2. PCR	187
6.2.4. Statistical analysis	188
6.3. Results	189
6.3.1. Efficacy of albendazole formulations against <i>C. parvum</i> <i>in vitro</i>	189
6.3.2. Efficacy of oryzalin formulations against <i>C. parvum</i> <i>in vitro</i>	190
6.4. Discussion	192
6.4.1. Albendazole	192
6.4.2. Oryzalin	193
6.4.3. Conclusion	193
Chapter 7. Antimalarial Effects of the Drug/HPβCD Complexes	195
7.1. Introduction	196
7.1.1. <i>Plasmodium</i>	196
7.1.1.1. Lifecycle of malaria	196
7.1.1.2. Human <i>Plasmodium</i>	198
7.1.2. Malaria	198

7.1.2.1. Prevalence	198
7.1.2.2. Clinical disease	199
7.1.2.3. Treatment and prevention	200
7.1.3. Preclinical assessment of antimalarials	201
7.1.4. Aim	202
7.2. Methods	203
7.2.1. <i>P. chabaudi</i>	203
7.2.2. <i>In vivo</i> parasite amplification for <i>in vitro</i> and <i>in vivo</i> drug studies	203
7.2.2.1. Origin and housing of experimental animals	203
7.2.2.2. Passage of <i>P. chabaudi</i> through mice	203
7.2.2.3. Infection and harvesting of <i>P. chabaudi</i> from donor rats for drug studies	204
7.2.2.4. Cryopreservation of <i>P. chabaudi</i>	204
7.2.2.5. Determination of parasitaemia and parasite titre	205
7.2.2.6. Anaesthesia and euthanasia	205
7.2.3. <i>In vitro</i> drug studies	206
7.2.3.1. Culture medium for <i>in vitro</i> drug studies	206
7.2.3.2. Preparation of drugs	206
7.2.3.3. <i>In vitro</i> drug efficacy studies	207
7.2.3.4. Determination of <i>in vitro</i> drug efficacy	207
7.2.4. <i>In vivo</i> drug studies	207
7.2.4.1. Mass infection of rats for <i>in vivo</i> drug studies	207
7.2.4.2. Drug formulations	208
7.2.4.3. <i>In vivo</i> drug efficacy studies	208
7.2.4.4. Determination of haematocrit values	209
7.2.4.5. Determination of <i>in vivo</i> drug efficacy	209
7.3. Results	210
7.3.1. Effect of HP β CD on <i>P. chabaudi in vitro</i>	210
7.3.2. <i>In vitro</i> drug studies	211
7.3.2.1. <i>In vitro</i> efficacy of CHQ, ABZ and OZ against <i>P. chabaudi</i>	211
7.3.2.2. <i>In vitro</i> efficacy of drug/HP β CD complexes against <i>P. chabaudi</i>	211
7.3.3. <i>In vivo</i> drug studies	211
7.4. Discussion	214
7.4.1. Effect of HP β CD <i>in vitro</i>	214
7.4.2. <i>In vitro</i> drug studies	216
7.4.3. <i>In vivo</i> drug studies	217
7.4.4. Conclusion	219
Chapter 8. General Discussion	221
8.1. Drug solubility and CD complexation	222
8.2. Albendazole CD complexation	224
8.3. CD complexation of the dinitroanilines	229
8.4. The role of cyclodextrins	231
8.5. Conclusion	233
Chapter 9. References	236
Chapter 10. Appendix	285
10.1. Biochemicals	286

ABBREVIATIONS

Acetonitrile	CH ₃ CN
Albendazole	ABZ
Albendazole sulfoxide	ABSO
Albendazole sulfone	ABSO ₂
Alsevier's solution (Section 7.2.2.4)	AS
Butylaminobenzoate	BAB
Chloroquine	CHQ
Cyclodextrin	CD
Differential scanning calorimetry –Thermogravimetric analysis	DSC-TGA
2,6-dimethyl-β-cyclodextrin	DMβCD
Dimethyl sulphoxide	DMSO
Distilled water	dH ₂ O
Foetal calf serum	FCS
Glucose Citrate Solution (Section 7.2.2.2)	GC
Guanosine triphosphate	GTP
High Performance Liquid Chromatography	HPLC
Hydroxyethyl-cyclodextrin	HECD
2-hydroxypropyl-cyclodextrin	2-HPCD
3-hydroxypropyl-cyclodextrin	3-HPCD
2-hydroxypropyl-β-cyclodextrin	HPβCD
Limit of detection (Section 2.2.2.2)	LOD
Limit of quantitation (Section 2.2.2.2)	LOQ
Mebendazole	MBZ
Microsomal flavin monooxygenases	MFMO
New born calf serum	NBCS
Oryzalin	OZ
Phosphate buffered saline (Section 5.2.1.1.4)	PBS
Randomly methylated-β-cyclodextrin	RMβCD
Red blood cells	RBC
Relative standard deviation (Section 3.2.3.1.5)	RSD
Stability constant (Section 1.6.1)	K _C
Sulfobutyl ether-β-cyclodextrin	SBEβCD
Tetrahydrofluran	THF
Thiabendazole	TBZ
Trifluralin	TF
2,3,6-trimethylmethyl-β-cyclodextrin	TMβCD
World Health Organization	WHO

LIST OF FIGURES

Figure 1.1: Chemical structure of α -CD, β -CD and γ -CD (Szejtli, 1988; Thompson, 1997).	6
Figure 1.2: Functional schematic of β -cyclodextrin (Szejtli, 1988; Thompson, 1997).	6
Figure 1.3: Scheme illustrating the association of free CD and drug to form a drug/cyclodextrin complex (Stella & Rajewski, 1997).	12
Figure 1.4: Potential structure of 2-hydroxypropyl- β -cyclodextrin with examples of substituents attached at the 2-, 3- and 6- positions (Pitha, 1990; Brewster, 1992; Thompson, 1997).	24
Figure 1.5: Phase solubility diagrams of Type A systems showing apparent increase in solubility of S caused by component L (Higuchi & Connors, 1965).	33
Figure 1.6: Phase solubility diagrams of Type B systems showing changes in solubility of S caused by component L (Higuchi & Connors, 1965).	33
Figure 2.1: Typical microtubules reach a dynamic equilibrium with tubulin, controlled by endogenous concentrations of co-factors such as GTP, Mg^{2+} , microtubule associated proteins (MAPs), Ca^{2+} and calmodulin. Text and figure from Lacey, (1990).	43
Figure 2.2: Primary substituent positions of the benzimidazole anthelmintics (Gottschoff et al., 1990; Townsend & Wise, 1990).	44
Figure 2.3: Chemical structure of some of the benzimidazole anthelmintics (Townsend & Wise, 1990).	45
Figure 2.4: The main metabolic pathways for ABZ (modified from Gyurik et al., 1981).	50
Figure 2.5: Substitution pattern of the 2,6-dinitroanilines (Probst et al., 1975).	51
Figure 2.6: Structure of trifluralin (Budavari, 1989).	54
Figure 2.7: Three pathways for TF metabolism are nitro reduction, <i>N</i> -dealkylation and hydroxylation (Emmerson & Anderson, 1966; Erkog & Menzer, 1985; Golab et al., 1969; Nelson et al., 1977).	55
Figure 2.8: Structure of OZ (Budavari, 1989).	57
Figure 2.9: UV spectrum of ABZ ($10 \mu\text{g mL}^{-1}$) in DMSO/methanol (0.5:99.5 v/v).	61
Figure 2.10: Chromatogram of ABZ ($10 \mu\text{g mL}^{-1}$ Att. 7), mobile phase consisted of 40% tetrahydrofuran, 1% formic acid and 59% water (v/v/v).	61
Figure 2.11: UV spectrum of TF ($10 \mu\text{g mL}^{-1}$) in methanol.	64
Figure 2.12: Chromatogram of TF ($4 \mu\text{g mL}^{-1}$ Att. 4), phase consisted of 65% acetonitrile and 35% water (v/v).	64
Figure 2.13: UV spectrum of OZ ($10 \mu\text{g mL}^{-1}$) in methanol.	67

Figure 2.14: Chromatogram of OZ (50 μ g mL ⁻¹ Att. 9), mobile phase consisted of 50% acetonitrile and 50% water (v/v).	67
Figure 2.15: Chromatogram of OZ (10 μ g mL ⁻¹ Att. 7), mobile phase consisted of 50% acetonitrile and 50% 100 mM phosphate buffer pH 3 (v/v).	67
Figure 2.16: Solubility of ABZ in the presence of HP β CD after 48 h at 25°C (mean \pm SE, n=3).	70
Figure 2.17: Effect of pH (50 mM phosphate buffer) on ABZ solubility after 2 days at room temperature (mean \pm SE, n=2).	72
Figure 2.18: Solubility of ABZ with varying pH and HP β CD concentrations (50 mM citric acid, n=1).	72
Figure 2.19: Solubility of ABZ with varying pH and HP β CD concentrations (50 mM phosphate buffer, n=1).	73
Figure 2.20: Effect of pH (50 mM phosphate buffer) on solubility of ABZ in the presence of HP β CD after incubation for 1 w at 35°C followed by 2 d at room temperature (n=1).	74
Figure 2.21: Effect of HP β CD on the solubility of ABZ at different pHs (50 mM phosphate buffer) after incubation for 1 w at 35°C followed by 2 d at room temperature (n=1).	75
Figure 2.22: Solubility of ABZ in the presence of HP β CD at pH 2 (500 mM phosphate buffer) after incubation for 1 w at 35°C followed by 2 d at room temperature (mean \pm SE, n=3).	75
Figure 2.24: Solubility of TF in the presence of HP β CD after 48 h at 25°C (mean \pm SE, n=3).	78
Figure 2.25: Solubility of OZ in the presence of HP β CD after 48 h at 25°C (mean \pm SE, n=3).	79
Figure 2.26: Effect of pH (50 mM phosphate buffer) on OZ solubility after 2 days at room temperature (mean \pm SE, n=2).	81
Figure 2.27: Solubility of OZ with varying pH and HP β CD concentrations (either 50 mM or 100 mM phosphate buffer, n=1).	81
Figure 2.28: Effect of pH (50-100 mM phosphate buffer) on solubility of OZ in the presence of HP β CD after equilibration for 1 w at 35°C, 2 d at room temperature (n=1).	82
Figure 2.29: Solubility of OZ in the presence of HP β CD at pH 11.2 (500 mM phosphate buffer) after equilibration for 1 w at 35°C, 2d at 21°C (mean \pm SE, n=1-3).	82
Figure 2.30: DSC-TGA thermograms (5°C/min) of (a) ABZ, (b) 60% HP β CD (w/v) pH 2.1 (200mM phosphate buffer) and (c) ABZ/HP β CD pH 2.1 (200mM phosphate buffer).	84
Figure 2.31: DSC-TGA thermograms (5°C/min) of (a) OZ, (b) 60% HP β CD (w/v) pH 11 (200mM phosphate buffer) and (c) OZ/HP β CD pH 11 (200mM phosphate buffer).	85

Figure 3.1: Schematic representation of the dissolution-dissociation-recrystallization process of a CD complex of a poorly water soluble guest. Text and figure from Szejtli, (1991a).	98
Figure 3.2: Theoretical blood level curves obtained after oral administration of a free drug (F) or its CD complexes with different stability constants. Text and figure from Szejtli, (1988).	99
Figure 3.3: UV spectrums of ABZ in 0.5% DMSO in methanol (a); ABSO in 0.5% DMSO in methanol (b); ABSO ₂ in 0.5% DMSO in methanol (c) and BAB in methanol (d) (10µg mL ⁻¹). 100% methanol was used as the blank.	105
Figure 3.4: Extraction procedure for the measurement of ABZ, ABSO, ABSO ₂ and BAB from plasma samples.	108
Figure 3.5: Extraction procedure for the measurement of OZ from plasma samples.	111
Figure 3.6: Chromatograms of blank rat plasma (Attn. 6) (a); spiked with ABZ (7.7 min), ABSO (3.6 min), ABSO ₂ (5.2 min) and BAB (8.7 min) (10 µg mL ⁻¹) (Attn. 7) (b); and plasma from rat treated orally with ABZ and spiked with BAB (10 µg mL ⁻¹) (Attn. 6) (c).	113
Figure 3.7: HPLC standard curves of ABZ, ABSO, ABSO ₂ and BAB using peak height (mean ± SE, n=3).	114
Figure 3.8: HPLC standard curves of ABZ, ABSO and ABSO ₂ using height ratio to BAB (10 µg mL ⁻¹) following extraction from spiked blank plasma (mean ± SE, n=3-13 – includes RSD values).	115
Figure 3.9: Plasma concentrations of ABSO (—) and ABSO ₂ (---) following oral administration of a commercial formulation of ABZ (Valbazen®) and ABZ/HPβCD in rats (6 mg kg ⁻¹) (mean ± SE, n=3).	116
Figure 3.10: Plasma concentrations of ABZ, ABSO and ABSO ₂ following oral administration of ABZ/HPβCD (pH 2.1) in rats (30 mg kg ⁻¹) (mean ± SE, n=3).	118
Figure 3.11: Plasma concentrations of ABZ, ABSO and ABSO ₂ following oral administration of ABZ (Suspension) in rats (30 mg kg ⁻¹) (mean ± SE, n=3).	118
Figure 3.12: Chromatogram of blank rat plasma (a) spiked with OZ (4.7 min) (2 µg mL ⁻¹) (b), and plasma from rat treated i.p. with OZ (c).	119
Figure 3.13: HPLC standard curve of OZ using peak area (r=0.9987) (mean ± SE, n=3).	120
Figure 3.14: HPLC standard curve of OZ following extraction from spiked blank plasma (r=0.987) (mean ± SE, n=3-15 – includes RSD values).	121
Figure 3.15: Plasma concentration of OZ following i.p. administration of OZ and OZ/HPβCD in rats (25 mg kg ⁻¹) (mean ± SE, n=3).	122
Figure 4.1: Cytotoxicity of HPβCD against HCT-8 cells after 24 h incubation (mean ± SE, n=4).	138

Figure 4.2: Average fluid consumption by five to seven-week-old rats given either water or HP β CD solution (mean, n=3).	139
Figure 4.3: Average fluid consumption by three-week-old rats given either water or HP β CD solution (mean, n=3).	140
Figure 5.1: <i>Giardia</i> lifecycle (Meyer, 1974).	147
Figure 5.2: Trophozoite and cyst morphology (Meyer, 1985).	147
Figure 5.3: Inhibitory effect of HP β CD on <i>Giardia</i> adherence to the culture vessel wall <i>in vitro</i> (mean \pm SE, n=3-15).	162
Figure 5.4: <i>In vitro</i> efficacy of three ABZ formulations against <i>Giardia</i> adherence to the culture vessel wall (mean \pm SE, n=3-21).	163
Figure 5.5: Effect of HP β CD on the efficacy of the ABZ/HP β CD complex against <i>Giardia</i> adherence to the culture vessel wall (mean \pm SE, n=3-10).	164
Figure 5.6: <i>In vivo</i> inhibitory effect of HP β CD on total <i>Giardia</i> number and <i>Giardia</i> trophozoites in the small intestine (mean \pm SE, n=3).	166
Figure 5.7: <i>In vivo</i> efficacy of ABZ (Valbazen®) and ABZ/HP β CD against trophozoite number in the small intestine of <i>Giardia</i> infected rats (mean \pm SE, n=3).	166
Figure 5.8: <i>In vivo</i> efficacy of ABZ (Valbazen®) and ABZ/HP β CD against overall <i>Giardia</i> number in <i>Giardia</i> infected rats (mean \pm SE, n=3).	167
Figure 6.1: Diagrammatic representation of the proposed lifecycle of <i>C. parvum</i> as it occurs in the mucosal epithelium of an infected mammalian host (Text and figure from Current & Blagburn, 1990, cited in Current & Garcia, 1991).	176
Figure 6.2: <i>In vitro</i> efficacy of ABZ and ABZ/HP β CD against <i>C. parvum</i> (mean \pm SE, n=4).	189
Figure 7.1: <i>Plasmodium</i> (<i>P. vivax</i>) lifecycle (Fujioka & Aikawa, 1999).	197
Figure 7.2: <i>In vitro</i> effect of HP β CD on <i>P. chabaudi</i> parasitaemia over 24 h (mean \pm SE, n=4).	210
Figure 7.3: <i>In vitro</i> effect of ABZ/HP β CD and OZ/HP β CD on <i>P. chabaudi</i> parasitaemia over 24 h (mean \pm SE, n=4). The HP β CD concentration of the formulations (when greater than 0.5%) is shown in brackets.	212
Figure 7.4: Course of infection in <i>P. chabaudi</i> infected rats, and when treated orally with 18 mg kg ⁻¹ day ⁻¹ CHQ on days 5-7 post-innoculation (mean \pm SE, n=8).	212

LIST OF TABLES

Table 1.1: Characteristics of α -CD, β -CD and γ -CDs (Szejtli, 1988; Connors, 1997).	6
Table 1.2: Some currently available CDs obtained by substitution of the OH groups located in the edge of the CD ring (Loftsson & Brewster, 1996).	19
Table 2.1: The effect of temperature and filtration on ABZ solutions.	71
Table 2.2: One way ANOVA of ABZ solubility, pH and HP β CD concentration.	73
Table 3.1: Preparation of standard commercial 'white drench' vehicle used in a number of commercial drenches.	103
Table 3.2: The HPLC detection and quantitation limits for ABZ, ABSO, ABSO ₂ and BAB following extraction from plasma.	112
Table 3.3: The RSD and Bias of the ABZ assay.	115
Table 3.4: Plasma concentrations of ABSO and ABSO ₂ after oral administrations of ABZ (Valbazen®) and ABZ/HP β CD (6 mg kg ⁻¹) (mean \pm SE, n=3).	116
Table 3.5: Plasma concentrations of ABSO and ABSO ₂ after oral administrations of ABZ (suspension) and ABZ/HP β CD (30 mg kg ⁻¹) (mean \pm SE, n=3).	117
Table 3.6: The RSD and Bias of the OZ assay.	121
Table 3.7: Plasma concentrations of OZ after oral administrations of OZ and OZ/HP β CD (25 mg kg ⁻¹) (mean \pm SE, n=3).	122
Table 5.1: BI-S-33 medium preparation for the cultivation of <i>G. duodenalis in vitro</i> .	154
Table 5.2: Scoring Method for the Assessment of Trophozoite Viability.	158
Table 5.3: The IC ₅₀ , MIC and MLC of three ABZ formulations against <i>G. duodenalis in vitro</i> .	164
Table 6.1: Medium preparation for the cultivation of HCT-8 cells.	184
Table 6.2: Medium preparation for the cultivation of <i>C. parvum in vitro</i> .	185
Table 6.3: The IC ₅₀ , MIC and MLC of two ABZ formulations against <i>C. parvum in vitro</i> .	190
Table 6.4: The IC ₅₀ , MIC and MLC of two OZ formulations against <i>C. parvum in vitro</i> .	190
Table 7.1: Medium used in drug experiments against <i>P. chabaudi in vitro</i> .	206
Table 7.2: Drug IC ₅₀ s against <i>P. chabaudi in vitro</i> .	211
Table 7.3: Therapeutic effects of oral ABZ and ABZ/HP β CD treatment in <i>P. chabaudi</i> infected rats.	213
Table 7.4: Drug IC ₅₀ s against <i>P. falciparum</i> , <i>P. berghei</i> and <i>P. chabaudi in vitro</i> .	217